Banco Santander S.A. lowered its position in Agilent Technologies Inc (NYSE:A) by 5.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,218 shares of the medical research company’s stock after selling 643 shares during the period. Banco Santander S.A.’s holdings in Agilent Technologies were worth $982,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in A. Vanguard Group Inc increased its position in Agilent Technologies by 0.8% during the 3rd quarter. Vanguard Group Inc now owns 24,155,483 shares of the medical research company’s stock valued at $1,703,929,000 after buying an additional 194,607 shares in the last quarter. Artisan Partners Limited Partnership lifted its position in Agilent Technologies by 0.6% during the first quarter. Artisan Partners Limited Partnership now owns 5,858,087 shares of the medical research company’s stock valued at $470,873,000 after purchasing an additional 36,359 shares in the last quarter. Geode Capital Management LLC lifted its position in Agilent Technologies by 7.2% during the fourth quarter. Geode Capital Management LLC now owns 4,234,035 shares of the medical research company’s stock valued at $285,139,000 after purchasing an additional 285,330 shares in the last quarter. Northern Trust Corp lifted its position in shares of Agilent Technologies by 1.5% in the first quarter. Northern Trust Corp now owns 3,864,956 shares of the medical research company’s stock valued at $310,666,000 after acquiring an additional 56,958 shares in the last quarter. Finally, Findlay Park Partners LLP purchased a new position in shares of Agilent Technologies in the fourth quarter valued at about $246,229,000.
Several brokerages have issued reports on A. UBS Group began coverage on Agilent Technologies in a research report on Friday, March 15th. They set a “buy” rating and a $92.00 target price for the company. Cowen boosted their target price on Agilent Technologies from $80.00 to $90.00 and gave the company an “outperform” rating in a research report on Tuesday, March 26th. Barclays lowered their price target on Agilent Technologies from $88.00 to $86.00 and set an “overweight” rating for the company in a report on Wednesday, May 15th. Bank of America lowered their price target on Agilent Technologies from $88.00 to $82.00 and set a “buy” rating for the company in a report on Wednesday, May 15th. Finally, Piper Jaffray Companies started coverage on Agilent Technologies in a report on Tuesday, June 11th. They issued an “overweight” rating and a $83.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $86.31.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.01). Agilent Technologies had a return on equity of 19.71% and a net margin of 22.25%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the prior year, the business earned $0.65 EPS. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. On average, equities research analysts anticipate that Agilent Technologies Inc will post 3.05 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be issued a $0.164 dividend. This represents a $0.66 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, July 1st. Agilent Technologies’s dividend payout ratio (DPR) is presently 23.66%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Recommended Story: How is a management fee different from a performance fee?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.